Bliss GVS Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Gagan Sharma

İcra Kurulu Başkanı

₹21.6m

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	3.5yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	6.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Gagan Sharma'un ücretlendirmesi Bliss GVS Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹634m
Jun 30 2024	n/a	n/a	₹815m
Mar 31 2024	₹22m	₹22m	₹755m
Dec 31 2023	n/a	n/a	₹879m
Sep 30 2023	n/a	n/a	₹883m
Jun 30 2023	n/a	n/a	₹598m
Mar 31 2023	₹18m	₹18m	₹709m
Dec 31 2022	n/a	n/a	₹871m
Sep 30 2022	n/a	n/a	₹91m
Jun 30 2022	n/a	n/a	₹165m
Mar 31 2022	₹15m	₹15m	₹150m
Dec 31 2021	n/a	n/a	₹17m
Sep 30 2021	n/a	n/a	₹773m
Jun 30 2021	n/a	n/a	₹766m
Mar 31 2021	₹1m	₹1m	₹685m

Tazminat ve Piyasa: Gagan 'nin toplam tazminatı ($USD 257.34K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 179.47K ).

Tazminat ve Kazançlar: Gagan 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Gagan Sharma (41 yo)

3.5yrs

Görev süresi

₹21,639,379

Tazminat

Mr. Gagan Harsh Sharma serves as Managing Director at Bliss GVS Pharma Limited since May 11, 2021 and its Director since January 21, 2021. He served as Vice President of Strategy and Business Development a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gagan Sharma	MD & Director	3.5yrs	₹21.64m	Veri yok
Deepak Sawant	Chief Financial Officer	1.9yrs	₹6.48m	Veri yok
Aditi Bhatt	Compliance Officer	6.3yrs	₹1.84m	Veri yok
Shruti Vishal Rao	Executive & Whole Time Director	no data	₹7.41m	2.01% ₹ 267.8m
Prashant Churi	Vice President of Technical Operations	no data	Veri yok	Veri yok
Vibha Sharma	Executive & Whole Time Director	no data	₹7.05m	2.35% ₹ 314.1m
Sourya Das	Associate Vice President	no data	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

41yo

Ortalama Yaş

Deneyimli Yönetim: 506197 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gagan Sharma	MD & Director	3.8yrs	₹21.64m	Veri yok
Shruti Vishal Rao	Executive & Whole Time Director	18.3yrs	₹7.41m	2.01% ₹ 267.8m
Vibha Sharma	Executive & Whole Time Director	16.3yrs	₹7.05m	2.35% ₹ 314.1m
Shilpa Bhatia	Independent Women Director	4.8yrs	₹375.00k	Veri yok
Santosh Parab	Independent Non-Executive Director	8.5yrs	₹375.00k	Veri yok
Nandkumar Chodankar	Non-Executive Independent Chairman	less than a year	Veri yok	Veri yok

6.6yrs

Ortalama Görev Süresi

45.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 506197 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.6 yıldır).

Bliss GVS Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Bliss GVS Pharma Limited Appoints Nandkumar Kashinath Chodankar as Chairman of the Board

Bliss GVS Pharma Limited Announces Cessation of Subramanian Ramaswamy Vaidya as an Independent Director

Bliss GVS Pharma Limited, Annual General Meeting, Jul 25, 2024

Insufficient new directors

Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao

Bliss GVS Pharma Limited, Annual General Meeting, Jun 19, 2023

Recent updates

Second quarter 2025 earnings released: EPS: ₹2.31 (vs ₹4.06 in 2Q 2024)

Investor sentiment deteriorates as stock falls 22%

Bliss GVS Pharma Limited Appoints Nandkumar Kashinath Chodankar as Chairman of the Board

Now 24% undervalued

Bliss GVS Pharma Limited to Report Q2, 2025 Results on Oct 24, 2024

Bliss GVS Pharma Limited to Report Q2, 2025 Results on Oct 24, 2024

Bliss GVS Pharma Limited Announces Cessation of Subramanian Ramaswamy Vaidya as an Independent Director

Investor sentiment improves as stock rises 16%

Bliss GVS Pharma Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Now 20% undervalued after recent price drop

Bliss GVS Pharma Limited to Report Q1, 2025 Results on Jul 24, 2024

Upcoming dividend of ₹0.50 per share

Full year 2024 earnings released: EPS: ₹7.23 (vs ₹6.83 in FY 2023)

Dividend of ₹0.50 announced

New minor risk - Share price stability

Now 23% undervalued after recent price drop

Full year 2024 earnings released: EPS: ₹7.23 (vs ₹6.83 in FY 2023)

Bliss GVS Pharma Limited, Annual General Meeting, Jul 25, 2024

Bliss GVS Pharma Limited to Report Q4, 2024 Results on May 02, 2024

Investor sentiment improves as stock rises 16%

Insufficient new directors

Third quarter 2024 earnings released: EPS: ₹2.64 (vs ₹2.68 in 3Q 2023)

New major risk - Share price stability

Bliss GVS Pharma Limited to Report Q3, 2024 Results on Jan 23, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹4.06 (vs ₹1.33 in 2Q 2023)

Investor sentiment improves as stock rises 20%

Bliss GVS Pharma Limited to Report First Half, 2024 Results on Nov 01, 2023

Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao

First quarter 2024 earnings released: EPS: ₹1.41 (vs ₹2.48 in 1Q 2023)

Bliss GVS Pharma Limited to Report Q1, 2024 Results on Aug 01, 2023

Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Investor sentiment improves as stock rises 17%

Upcoming dividend of ₹0.50 per share at 0.7% yield

Full year 2023 earnings released: EPS: ₹6.83 (vs ₹1.46 in FY 2022)

Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023

Bliss GVS Pharma Limited, Annual General Meeting, Jun 19, 2023

Bliss GVS Pharma Limited to Report Q4, 2023 Results on May 11, 2023

Insider recently bought ₹23m worth of stock

Third quarter 2023 earnings released: EPS: ₹2.68 (vs ₹4.83 loss in 3Q 2022)

Bliss GVS Pharma Limited to Report Q3, 2023 Results on Jan 24, 2023

Bliss GVS Pharma Limited Appoints Mr. Deepak Sawant as Chief Financial Officer

Second quarter 2023 earnings released: EPS: ₹1.33 (vs ₹2.05 in 2Q 2022)

Bliss GVS Pharma Limited to Report Q2, 2023 Results on Nov 07, 2022

First quarter 2023 earnings released: EPS: ₹2.48 (vs ₹2.35 in 1Q 2022)

Bliss GVS Pharma Limited to Report Q1, 2023 Results on Aug 03, 2022

Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹0.50 per share

Executive & Whole Time Director recently bought ₹21m worth of stock

Full year 2022 earnings released

Bliss GVS Pharma Limited Announces Resignation of Mr. Vipul B. Thakkar as Chief Financial Officer

Executive & Whole Time Director recently bought ₹9.5m worth of stock

Investor sentiment improved over the past week

Bliss GVS Pharma Limited, Annual General Meeting, Jun 28, 2022

Bliss GVS Pharma Limited to Report Q4, 2022 Results on Apr 30, 2022

Executive & Whole Time Director recently bought ₹26m worth of stock

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹2.05 (vs ₹1.99 in 2Q 2021)

Upcoming dividend of ₹0.50 per share

First quarter 2022 earnings released: EPS ₹2.35 (vs ₹1.57 in 1Q 2021)

Full year 2021 earnings released: EPS ₹6.64 (vs ₹9.43 in FY 2020)

Bliss GVS Pharma Limited Recommends Final Dividend for the Year Ended March 31, 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: ₹170

Third quarter 2021 earnings released: EPS ₹2.48

New 90-day high: ₹206

Bliss GVS Pharma Limited to Report Q3, 2021 Results on Jan 21, 2021